Stay updated on AbbVie Press Releases

Sign up to get notified when there's something new on the AbbVie Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AbbVie Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    New press releases were added to the All News section (21–24 days ago) and older items were removed (14–17 days ago), updating the News Center feed.
    Difference
    0.7%
    Check dated 2025-12-30T08:34:12.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    New items were added to the Latest news section (14–17 days ago) and older items removed (7–10 days ago), changing which press releases are visible.
    Difference
    1%
    Check dated 2025-12-23T08:10:58.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    News Center listings show routine timestamp updates (new items at 7, 9, and 10 days ago and deletions at 4 hours to 3 days ago), a minor, non-substantive change that does not affect core content or functionality; to avoid alerts for small changes, set an alert condition by clicking below.
    Difference
    1%
    Check dated 2025-12-16T02:32:53.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Added a December 2, 2025 press release: AbbVie to Feature New Data at ASH 2025, showcasing continued advances across novel treatment modalities in multiple blood cancers. Removed the November 18, 2025 press release announcing U.S. FDA approval of EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed or refractory follicular lymphoma.
    Difference
    8%
    Check dated 2025-12-08T20:22:32.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    New press releases and related social updates have been added, including the December 01, 2025 ECLIPSE data item and the November 24, 2025 Piper Sandler conference. Older items, including Genmab references and an FDA approval note, have been removed.
    Difference
    10%
    Check dated 2025-12-01T16:17:26.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    New items such as the FDA approval of EPKINLY (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma were added. Older entries were removed from the listing.
    Difference
    10%
    Check dated 2025-11-24T12:51:36.000Z thumbnail image

Stay in the know with updates to AbbVie Press Releases

Enter your email address, and we'll notify you when there's something new on the AbbVie Press Releases page.